Research Article
Predictive Model of Type 2 Diabetes Remission after Metabolic Surgery in Chinese Patients
Table 4
Univariate analysis of prolonged remission predictors.
| | | Remission group (N = 19) | Nonremission group (N = 31) | value |
| | Age (yr) | | | 0.274 | | <40 | 4 (66.67%) | 2 (33.33%) | | | ≥40 | 15 (34.09%) | 29 (65.91%) | | | Gender | | | 0.085 | | Female | 4 (22.22%) | 14 (77.78%) | | | Male | 15 (47.87%) | 17 (53.13%) | | | Duration (yr) | | | 0.121 | | ≤5 | 11 (50.00%) | 11 (50.00%) | | | >5 | 8 (28.57%) | 20 (71.43%) | | | Surgical procedures | | | 0.759 | | Sleeve gastrectomy | 2 (66.67%) | 1 (33.33%) | | | Gastric bypass | 20 (40.00%) | 30 (60.00%) | | | BMI (kg/m2) | | | 0.057 | | <27.5 | 6 (28.57%) | 15 (71.43%) | | | 27.5–32.5 | 8 (34.78%) | 15 (65.22%) | | | ≥32.5 | 5 (83.33%) | 1 (16.67%) | | | TG (mmol/L) | | | 0.923 | | ≥1.7 | 12 (37.50%) | 20 (62.50%) | | | <1.7 | 7 (38.89%) | 11 (61.11%) | | | CHOL (mmol/L) | | | 0.280 | | ≥4.14 | 15 (42.86%) | 20 (57.14%) | | | <4.14 | 4 (26.67%) | 11 (73.33%) | | | LDL (mmol/L) | | | 0.564 | | ≥2.59 | 8 (33.33%) | 16 (66.67%) | | | <2.59 | 11 (42.31%) | 15 (57.69%) | | | HDL (mmol/L) | | | 0.115 | | >1.29 | 6 (66.67%) | 3 (33.33%) | | | ≤1.29 | 13 (31.71%) | 28 (68.29%) | | | FPG (mmol/L) | | | 0.043 | | <7.0 | 11 (55.00%) | 9 (45.00%) | | | ≥7.0 | 8 (26.67%) | 22 (73.33%) | | | HbA1c (%) | | | 0.049 | | <6.5 | 2 (28.57%) | 5 (71.43%) | | | 6.5 ≤ HbA1c < 9 | 15 (51.72%) | 14 (48.28%) | | | ≥9 | 2 (14.29%) | 12 (85.71%) | | | FCP (ng/mL) | (N = 19) | (N = 31) | 0.923 | | ≤2.63 | 12 (37.00%) | 20 (62.50%) | | | >2.63 | 7 (38.89%) | 11 (61.11%) | | | ΔC30 (ng/mL) | (N = 18) | (N = 30) | 0.823 | | <1.01 | 9 (36.00%) | 16 (64.00%) | | | ≥1.01 | 9 (39.13%) | 14 (60.87%) | | | ΔC120 (ng/mL) | (N = 19) | (N = 31) | 0.777 | | ≤3.08 | 13 (39.39%) | 20 (60.61%) | | | >3.08 | 6 (35.29%) | 11 (64.71%) | | | ΔC30/ΔG30 (μg/mmol) | (N = 18) | (N = 30) | 0.654 | | ≤0.27 | 9 (34.62%) | 17 (65.38%) | | | >0.27 | 9 (40.91%) | 13 (59.09%) | | | ΔC120/ΔG120 (μg/mmol) | (N = 19) | (N = 31) | 0.812 | | ≤0.42 | 11 (36.67%) | 19 (63.33%) | | | >0.42 | 8 (40.00%) | 12 (60.00%) | | | HOMA-β (CP, DM) (%) | (N = 19) | (N = 31) | 0.233 | | ≤52.71 | 9 (31.03%) | 20 (68.97%) | | | >52.71 | 10 (47.62%) | 11 (52.38%) | | | HOMA-IR (CP) | (N = 19) | (N = 31) | 0.640 | | ≤2.08 | 11 (35.48%) | 20 (64.52%) | | | >2.08 | 8 (42.11%) | 11 (57.89%) | | | C-peptide AUC (ng/ml) | (N = 18) | (N = 30) | 0.045 | | ≤30.93 | 8 (26.67%) | 22 (73.33%) | | | >30.93 | 10 (55.56%) | 8 (44.44%) | | | UmAlb (mg/L) | (N = 16) | (N = 28) | 0.596 | | <20 | 6 (46.15%) | 7 (53.85%) | | | ≥20 | 10 (32.66%) | 21 (67.74%) | | | Preoperative insulin use | | | 0.405 | | Yes | 10 (33.33%) | 20 (66.67%) | | | No | 9 (45.00%) | 11 (55.00%) | |
|
|
; indexes of islet function (FCP, ΔC30, ΔC120, ΔC30/ΔG30, ΔC120/ΔG120, HOMA- β (CP, DM), HOMA-IR (CP), and C-peptide AUC) were grouped by median. |
